NCT05945875
- Conditions
- Carcinoma, Carcinoma, Squamous Cell, Head and Neck Neoplasms, +7 more
- Locations
-
- Vanderbilt University/Ingram Cancer Center Nashville, Tennessee, United States
Clinical trial condition
Recurrent Head and Neck Squamous Cell Carcinoma
Explore clinical trials studying Recurrent Head and Neck Squamous Cell Carcinoma. Study availability and eligibility vary by location and protocol.
43 public trials
21 recruiting studies
Recurrent Head and Neck Squamous Cell Carcinoma trial results
Not yet recruiting
Anti-PD-1 Therapy in Recurrent and Metastatic Head and Neck Squamous Cell Carcinoma
NCT07751289
- Conditions
- Carcinoma, Carcinoma, Squamous Cell, Head and Neck Neoplasms, +6 more
- Locations
-
Not specified
Enrolling by invitation
BRIDGE Study: Neoadjuvant Finotonlimab, Cetuximab, and Docetaxel in Resectable Recurrent HNSCC After Immunotherapy Progression
NCT07618624
- Conditions
- Carcinoma, Carcinoma, Squamous Cell, Head and Neck Cancer, +7 more
- Locations
-
- The First People's Hospital of Foshan Foshan, Guangdong, China
- Affiliated Cancer Hospital and Institute of Guangzhou Medical University Guangzhou, Guangdong, China
- Guangzhou First People's Hospital Guangzhou, Guangdong, China
- Sun Yat-sen University Cancer Center Guangzhou, Guangdong, China
Active, not recruiting
Testing the Addition of an Anti-cancer Drug, Ipatasertib, to the Usual Immunotherapy Treatment (Pembrolizumab) in Patients With Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck
NCT05172258
- Conditions
- Carcinoma, Carcinoma, Squamous Cell, Head and Neck Neoplasms, +32 more
- Locations
-
- City of Hope Comprehensive Cancer Center Duarte, California, United States
- City of Hope at Irvine Lennar Irvine, California, United States
- City of Hope Antelope Valley Lancaster, California, United States
- Keck Medicine of USC Koreatown Los Angeles, California, United States
Active, not recruiting
Testing the Addition of an Anti-cancer Drug, BAY 1895344, With Radiation Therapy to the Usual Pembrolizumab Treatment for Recurrent Head and Neck Cancer
NCT04576091
- Conditions
- Carcinoma, Carcinoma, Squamous Cell, Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, +52 more
- Locations
-
- Los Angeles General Medical Center Los Angeles, California, United States
- USC / Norris Comprehensive Cancer Center Los Angeles, California, United States
- Northwestern University Chicago, Illinois, United States
- Montefiore Medical Center-Einstein Campus The Bronx, New York, United States
Active, not recruiting
CIMAvax Vaccine, Nivolumab, and Pembrolizumab in Treating Patients With Advanced Non-small Cell Lung Cancer or Squamous Head and Neck Cancer
NCT02955290
- Conditions
- Advanced Head and Neck Squamous Cell Carcinoma, Advanced Squamous Non-Small Cell Lung Carcinoma, Bronchial Neoplasms, +29 more
- Locations
-
- Indiana University Melvin and Bren Simon Comprehensive Cancer Center Indianapolis, Indiana, United States
- Roswell Park Cancer Institute Buffalo, New York, United States
- St. Francis Hospital Roslyn, New York, United States
- Good Samaritan Hospital West Islip, New York, United States
Active, not recruiting
Testing the Use of Investigational Drugs Atezolizumab and/or Bevacizumab With or Without Standard Chemotherapy in the Second-Line Treatment of Advanced-Stage Head and Neck Cancers
NCT05063552
- Conditions
- Carcinoma, Carcinoma, Squamous Cell, Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, +45 more
- Locations
-
- University of Arkansas for Medical Sciences Little Rock, Arkansas, United States
- Epic Care-Dublin Dublin, California, United States
- Epic Care Partners in Cancer Care Emeryville, California, United States
- UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care Irvine, California, United States
Active, not recruiting
Cetuximab and Recombinant Interleukin-12 in Treating Patients With Squamous Cell Carcinoma of the Head and Neck That is Recurrent, Metastatic, or Cannot Be Removed by Surgery
NCT01468896
- Conditions
- Carcinoma, Carcinoma, Squamous Cell, Head and Neck Neoplasms, +8 more
- Locations
-
- MedStar Georgetown University Hospital Washington D.C., District of Columbia, United States
- Ohio State University Comprehensive Cancer Center Columbus, Ohio, United States
Active, not recruiting
Cemiplimab, Low-Dose Paclitaxel and Carboplatin for the Treatment of Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck
NCT04862650
- Conditions
- Carcinoma, Carcinoma, Squamous Cell, Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, +43 more
- Locations
-
- Ohio State University Comprehensive Cancer Center Columbus, Ohio, United States
Active, not recruiting
Sorafenib in Combination With Carboplatin and Paclitaxel in Treating Participants With Metastatic or Recurrent Head and Neck Squamous Cell Cancer
NCT00494182
- Conditions
- Carcinoma, Carcinoma, Squamous Cell, Head and Neck Neoplasms, +15 more
- Locations
-
- M D Anderson Cancer Center Houston, Texas, United States